The Duke Center for Brain and Spine Metastasis (DCBSM) is hosting professor Michael Davies, MD, PhD, chairman of the Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, for a lecture — "The Final Frontier: Advances in the Understanding and Treatment of Melanoma Brain Metastases" — on Wednesday, February 19.
Davies also holds joint appointments in the Departments of Systems Biology and Translational Molecular Pathology.
Davies is an expert in the management of patients with advanced melanoma, including treatment with immunotherapy, targeted therapy, and chemotherapy, as well as the development of integrated multidisciplinary care plans. In addition to providing standard of care therapies, he has designed and led multiple clinical trials for patients with metastatic melanoma.
Davies has been the principal investigator of both individual and team science peer-reviewed grants from several organizations, including the National Cancer Institute, the US Department of Defense, the American Society of Clinical Oncology, the American Cancer Society, the Melanoma Research Alliance, and the Melanoma Research Foundation.
The leader of a translational laboratory research program, Davies' research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, particularly in therapeutic resistance and in the molecular pathogenesis of brain metastases.
He has authored or co-authored more than 180 original research manuscripts in peer-reviewed journals including Cell, Cancer Cell, Science, Cancer Discovery, Lancet Oncology, Cancer Research, JAMA Oncology, and Clinical Cancer Research. Davies is a member of the American Society for Clinical Investigation and the Executive Committee of the Society for Melanoma Research.
Davies' talk will be held from 4 p.m. to 5 p.m. at Duke South Ampitheater. It's part of the DCBSM's Invited Professor Lecture Series.
Feb. 19, 2020
4 p.m. to 5 p.m.
Duke South Ampitheater